Cargando…

Respiratory Syncytial Virus Infects Primary Neonatal and Adult Natural Killer Cells and Affects Their Antiviral Effector Function

BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of severe acute lower respiratory tract infections in infants. Natural killer (NK) cells are important antiviral effector cells that likely encounter RSV in the presence of virus-specific (maternal) antibodies. As NK cells potentially co...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Erp, Elisabeth A, Feyaerts, Dorien, Duijst, Maxime, Mulder, H Lie, Wicht, Oliver, Luytjes, Willem, Ferwerda, Gerben, van Kasteren, Puck B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376914/ https://www.ncbi.nlm.nih.gov/pubmed/30252097 http://dx.doi.org/10.1093/infdis/jiy566

Ejemplares similares

Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
por: van Erp, Elisabeth A., et al.
Publicado: (2019)

Pathogenesis of Respiratory Syncytial Virus Infection in BALB/c Mice Differs Between Intratracheal and Intranasal Inoculation
por: van Erp, Elisabeth A., et al.
Publicado: (2019)

In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants
por: van Erp, Elisabeth A., et al.
Publicado: (2017)

Natural killer cell activation by respiratory syncytial virus‐specific antibodies is decreased in infants with severe respiratory infections and correlates with Fc‐glycosylation
por: van Erp, Elisabeth A, et al.
Publicado: (2020)

Binding of respiratory syncytial virus particles to platelets does not result in their degranulation in vitro
por: Lakerveld, Anke J., et al.
Publicado: (2023)

Viral Infection of Human Natural Killer Cells
por: van Erp, Elisabeth A., et al.
Publicado: (2019)

Antibody and Local Cytokine Response to Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults
por: Yu, Xiao, et al.
Publicado: (2020)

Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age
por: Jans, Jop, et al.
Publicado: (2017)

Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study
por: DeVincenzo, John, et al.
Publicado: (2020)

Recurrent Respiratory Syncytial Virus Infection in a CD14-Deficient Patient
por: Besteman, Sjanna B, et al.
Publicado: (2022)

Aptamers for respiratory syncytial virus detection
por: Percze, Krisztina, et al.
Publicado: (2017)

Estimation of the Number of Respiratory Syncytial Virus–Associated Hospitalizations in Adults in the European Union
por: Osei-Yeboah, Richard, et al.
Publicado: (2023)

Transmission of Respiratory Syncytial Virus Infection Within Families
por: Heikkinen, Terho, et al.
Publicado: (2014)

Antibody Correlates of Protection From Severe Respiratory Syncytial Virus Disease in a Vaccine Efficacy Trial
por: Fong, Youyi, et al.
Publicado: (2023)

A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats
por: Widjojoatmodjo, Myra N, et al.
Publicado: (2010)

Epidemiology and Characteristics of Respiratory Syncytial Virus Pneumonia in Critically Ill Adults
por: Kim, Taeeun, et al.
Publicado: (2023)

Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012
por: Pastula, Susan T., et al.
Publicado: (2017)

Respiratory syncytial virus is an “opportunistic” killer
por: Caballero, Mauricio T., et al.
Publicado: (2018)

Younger Children Develop Higher Effector Antibody Responses to SARS-CoV-2 Infection
por: Tomasi, Lisa, et al.
Publicado: (2022)

Actin- and clathrin-dependent mechanisms regulate interferon gamma release after stimulation of human immune cells with respiratory syncytial virus
por: Jans, Jop, et al.
Publicado: (2016)

Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens
por: Akiyama, Matthew J, et al.
Publicado: (2021)

In Utero Activation of Natural Killer Cells in Congenital Cytomegalovirus Infection
por: Vaaben, Anna V, et al.
Publicado: (2022)

Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged ≤5 Years (INSPIRE Study)
por: Hartmann, Katrin, et al.
Publicado: (2022)

Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A Systematic Review and Meta-analysis
por: Onwuchekwa, Chukwuemeka, et al.
Publicado: (2023)

Severity of Respiratory Syncytial Virus Lower Respiratory Tract Infection With Viral Coinfection in HIV-Uninfected Children
por: Mazur, Natalie I., et al.
Publicado: (2017)

Transmission of Respiratory Syncytial Virus Among Children Under 5 Years in Households of Rural Communities, the Philippines
por: Otomaru, Hirono, et al.
Publicado: (2019)

Impact of the Coronavirus Disease 2019 Pandemic on the Clinical Features of Pediatric Respiratory Syncytial Virus Infection in Japan
por: Ozeki, Shoko, et al.
Publicado: (2022)

Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study
por: Isfordink, Cas J, et al.
Publicado: (2021)

Respiratory Syncytial Virus–Related Complications and Healthcare Costs Among a Medicare-Insured Population in the United States
por: DeMartino, Jessica K, et al.
Publicado: (2023)

Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years
por: Del Riccio, Marco, et al.
Publicado: (2023)

Respiratory Syncytial Virus Incidence and Severity in a Community-Based Prospective Cohort of Children Aged 0–14 Years
por: Smith, Matthew, et al.
Publicado: (2022)

Pneumococcal Conjugate Vaccines Are Protective Against Respiratory Syncytial Virus Hospitalizations in Infants: A Population-Based Observational Study
por: Le, Huong, et al.
Publicado: (2023)

Viral Genetic Determinants of Prolonged Respiratory Syncytial Virus Infection Among Infants in a Healthy Term Birth Cohort
por: Lawless, Dylan, et al.
Publicado: (2022)

Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine
por: Jordan, Elke, et al.
Publicado: (2023)

Age-Dependent Risk of Respiratory Syncytial Virus Infection: A Systematic Review and Hazard Modeling From Serological Data
por: Nakajo, K, et al.
Publicado: (2023)

Hyperinflammatory Syndrome, Natural Killer Cell Function, and Genetic Polymorphisms in the Pathogenesis of Severe Dengue( )
por: Vuong, Nguyen Lam, et al.
Publicado: (2022)

Incidence of Medically Attended Respiratory Syncytial Virus and Influenza Illnesses in Children 6–59 Months Old During Four Seasons
por: Simpson, Melissa D., et al.
Publicado: (2016)

Factors Predicting Secondary Respiratory Morbidity Following Early-Life Respiratory Syncytial Virus Infections: Population-Based Cohort Study
por: Sarna, Mohinder, et al.
Publicado: (2023)

Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis
por: Onwuchekwa, Chukwuemeka, et al.
Publicado: (2023)

Systematic Literature Review of Risk Factors for Poor Outcomes Among Adults With Respiratory Syncytial Virus Infection in High-Income Countries
por: Njue, Annete, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_00qtetf69buk3s5srrtulgj3no